| Synonyms: | |
| Status: | Phase 2 |
| Entry Type: | Small molecule |
| Molecule Category: | UNKNOWN |
| UNII: | U4017GUQ06 |
| InChI Key | GCWIQUVXWZWCLE-INIZCTEOSA-N |
|---|---|
| Smile | |
| InChI |
|
| Property Name | Value |
|---|---|
| Molecular Formula | C20H16ClN3O2 |
| Molecular Weight | 365.82 |
| AlogP | 4.07 |
| Hydrogen Bond Acceptor | 4.0 |
| Hydrogen Bond Donor | 1.0 |
| Number of Rotational Bond | 3.0 |
| Polar Surface Area | 81.48 |
| Molecular species | NEUTRAL |
| Aromatic Rings | 3.0 |
| Heavy Atoms | 26.0 |
| Action | Mechanism of Action | Reference |
|---|---|---|
| INHIBITOR | Bromodomain and extra-terminal motif (BET) inhibitor | PubMed PubMed ClinicalTrials |
| Targets | EC50(nM) | IC50(nM) | Kd(nM) | Ki(nM) | Inhibition(%) | |
|---|---|---|---|---|---|---|
|
Epigenetic regulator
Reader
Bromodomain
|
- | 18-39 | - | - | - |
| Mesh Heading | Maximum Phase | Mesh ID | Reference |
|---|---|---|---|
| Peripheral Nervous System Neoplasms | 2 | D010524 | ClinicalTrials |
| Myelodysplastic Syndromes | 1 | D009190 | ClinicalTrials |
| Leukemia, Myeloid, Acute | 1 | D015470 | ClinicalTrials |
| Lymphoma | 1 | D008223 | ClinicalTrials |
| Multiple Myeloma | 1 | D009101 | ClinicalTrials |
| Primary Myelofibrosis | 1 | D055728 | ClinicalTrials |
| Resources | Reference |
|---|---|
| ChEMBL | CHEMBL4303404 |
| FDA SRS | U4017GUQ06 |
| Guide to Pharmacology | 9120 |
| PDB | 62G |
| SureChEMBL | SCHEMBL15926539 |
| ZINC | ZINC000200480149 |